Oncology Information for Grant Submissions
Bayer funds educational programs advancing knowledge of new therapies, treatment strategies, and quality of life in advanced prostate cancer.
Funder: Bayer
Due Dates: Rolling monthly review (allow minimum 45 days for response)
Funding Amounts: Amount varies by project; detailed budget required in application.
Summary: Supports educational programs advancing knowledge and management of prostate cancer, with emphasis on new therapies, treatment sequencing, and quality of life.
Key Information: Grant applications must align with ACCME guidelines and include detailed supporting documentation.
Description
Bayer Oncology Medical Affairs is seeking grant applications for educational initiatives focused on prostate cancer, including non-metastatic castrate resistant prostate cancer (nmCRPC), metastatic castrate resistant prostate cancer (mCRPC), and metastatic hormone-sensitive prostate cancer (mHSPC). Priority areas include the use of novel anti-hormonal agents and alpha-emitting therapies, advanced treatment algorithms, therapy sequencing, management of comorbidities and adverse events, and the impact of these factors on patient quality of life. Grants aim to support programs that address evolving treatment landscapes and improve outcomes for patients with advanced prostate cancer.
